November 14, 2016

Verseon to Present New Preclinical Safety and Tolerability Results at the 2016 American Heart Association’s Scientific Sessions

Fremont, Calif.—Verseon will present new preclinical data on its novel class of oral anticoagulants at the American Heart Association’s Scientific Sessions in New Orleans on November 15. The poster will feature pharmacokinetics across several species as well as toxicity, safety, and tolerability data that further expand Verseon’s comprehensive preclinical studies of its anticoagulant candidates.

Using its proprietary, computer-driven discovery platform, Verseon designs drug candidates that are unlikely to be found by traditional drug discovery methods. The Company is advancing a class of potent, highly selective direct thrombin inhibitors that bind to thrombin through a unique mode of action via reversible covalent inhibition.

In preclinical research, Verseon’s direct thrombin inhibitors show bioavailability comparable to or better than currently available anticoagulants, suggesting that they may be suitable for oral dosing. In addition, preclinical testing indicates that these inhibitors carry lower bleeding risk compared to existing anticoagulants. The Company believes that this novel class of anticoagulants could provide new therapies for thrombotic disorders with enhanced benefit-risk profiles.

Details of the poster, to be revealed at the American Heart Association conference, are as follows:

Poster Title: Novel, Highly Selective Direct Thrombin Inhibitors: Efficacy, Safety, and Tolerability Studies
Poster Number: T1204
Session Name: Thrombosis, Immunity and Inflammation
Date and Time: November 15, 2016, 12:45-2:00 PM
Location: Science and Technology Hall, Basic Science Section

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

-Ends-

For further information please contact

Verseon Corporation
Arthur Shmurun / Amy Thai +1 (510) 225 9000
Cenkos Securities (NOMAD and Joint Broker)
Mark Connelly / Steve Cox +44 (0) 20 7397 8900
Cantor Fitzgerald Europe (Joint Broker)
Marc Milmo / Phil Davies / Callum Butterfield +44 (0) 20 7894 7000
Mirabaud Securities LLP (Joint Broker)
Peter Krens +44 (0) 20 7321 2508

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)
Henry Harrison-Topham / Sophie Cowles +44 (0) 20 7466 5000

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, WHICH ARE GENERALLY STATEMENTS THAT ARE NOT HISTORICAL FACTS. FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE WORDS "EXPECTS," "ANTICIPATES," "BELIEVES," "INTENDS," "ESTIMATES," "PLANS," "WILL," “OUTLOOK” AND SIMILAR EXPRESSIONS. FORWARD-LOOKING STATEMENTS ARE BASED ON MANAGEMENT’S CURRENT PLANS, ESTIMATES, ASSUMPTIONS AND PROJECTIONS, AND SPEAK ONLY AS OF THE DATE THEY ARE MADE. WE UNDERTAKE NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENT IN LIGHT OF NEW INFORMATION OR FUTURE EVENTS, EXCEPT AS OTHERWISE REQUIRED BY LAW. FORWARD-LOOKING STATEMENTS INVOLVE INHERENT RISKS AND UNCERTAINTIES, MOST OF WHICH ARE DIFFICULT TO PREDICT AND ARE GENERALLY BEYOND OUR CONTROL. ACTUAL RESULTS OR OUTCOMES MAY DIFFER MATERIALLY FROM THOSE IMPLIED BY THE FORWARD-LOOKING STATEMENTS AS A RESULT OF THE IMPACT OF A NUMBER OF FACTORS.

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods

 

Drug Programs

Multiple therapeutic areas, all with unmet (or poorly met) medical needs